Advanced search
Publication Cover
OncoImmunology Volume 1, 2012 - Issue 2
Submit an article Journal homepage
897
Views
18
CrossRef citations to date
0
Altmetric
Author's View

Systemic cancer immunotherapy with Toll-like receptor 7 agonists

Timing is everything

Christian Hotz Center for Integrated Protein Science Munich (CIPSM); Division of Clinical Pharmacology; Department of Internal Medicine; Ludwig-Maximilian University of Munich; Munich, Germany; Department of Medicine; University of Fribourg; Fribourg, Switzerland
&
Carole Bourquin Center for Integrated Protein Science Munich (CIPSM); Division of Clinical Pharmacology; Department of Internal Medicine; Ludwig-Maximilian University of Munich; Munich, Germany; Department of Medicine; University of Fribourg; Fribourg, SwitzerlandCorrespondence[email protected]
Pages 227-228 | Published online: 01 Mar 2012

References

  • Peris K, Campione E, Micantonio T, Marulli GC, Fargnoli MC, Chimenti S. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. Dermatol Surg 2005; 31:318 - 23; http://dx.doi.org/10.1111/j.1524-4725.2005.31081; PMID: 15841634
  • Bourquin C, Schmidt L, Lanz AL, Storch B, Wurzenberger C, Anz D, et al. Immunostimulatory RNA oligonucleotides induce an effective antitumoral NK cell response through the TLR7. J Immunol 2009; 183:6078 - 86; http://dx.doi.org/10.4049/jimmunol.0901594; PMID: 19890064
  • Anz D, Koelzer VH, Moder S, Thaler R, Schwerd T, Lahl K, et al. Immunostimulatory RNA blocks suppression by regulatory T cells. J Immunol 2010; 184:939 - 46; http://dx.doi.org/10.4049/jimmunol.0901245; PMID: 19966212
  • Zoglmeier C, Bauer H, Norenberg D, Wedekind G, Bittner P, Sandholzer N, et al. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin Cancer Res 2011; 17:1765 - 75; http://dx.doi.org/10.1158/1078-0432.CCR-10-2672; PMID: 21233400
  • Dummer R, Hauschild A, Becker JC, Grob JJ, Schadendorf D, Tebbs V, et al. An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin Cancer Res 2008; 14:856 - 64; http://dx.doi.org/10.1158/1078-0432.CCR-07-1938; PMID: 18245549
  • Geller MA, Cooley S, Argenta PA, Downs LS, Carson LF, Judson PL, et al. Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunol Immunother 2010; 59:1877 - 84; http://dx.doi.org/10.1007/s00262-010-0914-1; PMID: 20820775
  • Rajagopal D, Paturel C, Morel Y, Uematsu S, Akira S, Diebold SS. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. Blood 2010; 115:1949 - 57; http://dx.doi.org/10.1182/blood-2009-08-238543; PMID: 20065291
  • Broad A, Kirby JA, Jones DE. Toll-like receptor interactions: tolerance of MyD88-dependent cytokines but enhancement of MyD88-independent interferon-beta production. Immunology 2007; 120:103 - 11; http://dx.doi.org/10.1111/j.1365-2567.2006.02485.x; PMID: 17034424
  • Bourquin C, Hotz C, Noerenberg D, Voelkl A, Heidegger S, Roetzer LC, et al. Systemic Cancer Therapy with a Small Molecule Agonist of Toll-like Receptor 7 Can Be Improved by Circumventing TLR Tolerance. Cancer Res 2011; 71:5123 - 33; http://dx.doi.org/10.1158/0008-5472.CAN-10-3903; PMID: 21697281
  • Bogunovic D, Manches O, Godefroy E, Yewdall A, Gallois A, Salazar AM, et al. TLR4 Engagement during TLR3-Induced Proinflammatory Signaling in Dendritic Cells Promotes IL-10-Mediated Suppression of Antitumor Immunity. Cancer Res 2011; 71:5467 - 76; http://dx.doi.org/10.1158/0008-5472.CAN-10-3988; PMID: 21730023

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.